• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta Radiologica >Hepatic contrast medium enhancement at computed tomography and its correlation with various body size measures
【24h】

Hepatic contrast medium enhancement at computed tomography and its correlation with various body size measures

机译：电脑断层扫描对肝脏造影剂的增强作用及其与各种体型测量的相关性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: When the same dose of iodine is given to all patients when performing abdominal computed tomography (CT) there may be a wide inter-individual variation in contrast medium (CM) enhancement of the liver. Purpose: To evaluate if any of the measures body height (BH), body mass index (BMI), lean body mass (LBM), ideal body weight (IBW), and body surface area (BSA) correlated better than body weight (BW) with hepatic enhancement, and to compare the enhancement when using iodixanol and iomeprol. Material and Methods: One hundred patients referred for standard three-phase CT examination of abdomen were enrolled. Body weight and height were measured at the time of the CT examination. Forty grams of iodine (iodixanol 320 mg I/mL or iomeprol 400 mg I/mL) was injected at a rate of 1.6 g-I/s, followed by a 50 mL saline flush. The late arterial phase was determined by using a semi-automatic smart prep technique with a scan delay of 20 s. The hepatic parenchymal phase started automatically 25 s after the late arterial phase. CM concentration was estimated by placement of regions of interest in aorta (native and late arterial phase) and in liver (native and parenchymal phase). Results: BW (r = 20.51 and 20.64), LBM (r = 20.54 and 20.59), and BSA (r = 20.54 and 20.65) showed the best correlation coefficients with aortic and hepatic parenchymal enhancement, respectively, without any significant differences between the measures. Comparing iodixanol and iomeprol there was no significant difference in aortic enhancement. The liver enhancement was significantly higher (P < 0.05) using iodixanol than iomeprol. Conclusion: To achieve a consistent hepatic enhancement, CM dose may simply be adjusted to body weight instead of using more complicated calculated parameters based on both weight and height.
机译：背景：在进行腹部计算机断层扫描（CT）时，如果对所有患者给予相同剂量的碘，则肝脏造影剂（CM）增强的个体间差异可能很大。目的：评估身高（BH），体重指数（BMI），瘦体重（LBM），理想体重（IBW）和体表面积（BSA）的相关性是否比体重（BW）好）增强肝功能，并比较使用碘克沙醇和碘美普尔时的增强效果。资料与方法：纳入一百名接受标准腹部三期CT检查的患者。在CT检查时测量体重和身高。以1.6 g-I / s的速率注射40克碘（碘克沙醇320 mg I / mL或iomeprol 400 mg I / mL），然后冲洗50 mL盐水。通过使用半自动智能准备技术（扫描延迟为20 s）确定动脉晚期。肝实质期在动脉晚期后25 s自动开始。通过在主动脉（天然和动脉晚期）和肝脏（天然和实质期）中感兴趣的区域的位置来估计CM浓度。结果：BW（r = 20.51和20.64），LBM（r = 20.54和20.59）和BSA（r = 20.54和20.65）分别显示了与主动脉和肝实质增强相关的最佳相关系数，但两种方法之间没有显着差异。比较碘克沙醇和碘美普尔，主动脉增强无明显差异。使用碘克沙醇的肝功能明显高于碘美普尔（P <0.05）。结论：为了获得持续的肝脏增强效果，可以简单地将CM剂量调整为体重，而不是使用基于体重和身高的更复杂的计算参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号